Equities
  • Price (EUR)9.00
  • Today's Change0.05 / 0.56%
  • Shares traded0.00
  • 1 Year change+5.88%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aspen Pharmacare Holdings Limited is a South Africa-based global specialty and branded multinational pharmaceutical company. The Company focuses on marketing and manufacturing a range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets. Its segments include Prescription, Over the counter (OTC), Injectables, Active Pharmaceutical Ingredients (API), Finished Dose Form (FDF) and Heparin. It offers sterile products in injectable form primarily administered in hospitals and also those prescribed and administered by either physicians or in a retail pharmacy environment. Its key brands include Arixtra, Diprivan, Fraxiparine, Marcaine, Sustanon and Xylocaine (Injectables). Its OTC segment includes products that do not require prescriptions and are primarily sold in the retail pharmacy and fast-moving consumer goods sectors. Its Prescription segment includes products which generally require a prescription from a healthcare professional.

  • Revenue in ZAR (TTM)44.71bn
  • Net income in ZAR4.40bn
  • Incorporated1985
  • Employees8.87k
  • Location
    Aspen Pharmacare Holdings LtdAspen Place, 9 Rydall Vale ParkDouglas Saunders Drive ,La Lucia RidgeLA LUCIA South AfricaZAF
  • Phone+27 315808600
  • Fax+27 112396111
  • Websitehttp://www.aspenpharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.